Cetera Investment Advisers Buys 3,767 Shares of Illumina, Inc. (NASDAQ:ILMN)

Cetera Investment Advisers increased its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 25.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 18,384 shares of the life sciences company’s stock after acquiring an additional 3,767 shares during the quarter. Cetera Investment Advisers’ holdings in Illumina were worth $1,919,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of ILMN. Trivant Custom Portfolio Group LLC increased its position in Illumina by 166.7% during the first quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock worth $27,000 after acquiring an additional 125 shares during the period. Versant Capital Management Inc increased its holdings in Illumina by 292.9% in the 2nd quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock valued at $34,000 after buying an additional 246 shares during the period. Industrial Alliance Investment Management Inc. bought a new stake in Illumina in the 2nd quarter valued at $34,000. Massmutual Trust Co. FSB ADV increased its holdings in Illumina by 86.8% in the 1st quarter. Massmutual Trust Co. FSB ADV now owns 284 shares of the life sciences company’s stock valued at $39,000 after buying an additional 132 shares during the period. Finally, Itau Unibanco Holding S.A. bought a new stake in Illumina in the 2nd quarter valued at $61,000. Institutional investors own 89.42% of the company’s stock.

Illumina Stock Performance

Illumina stock opened at $145.54 on Monday. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04. Illumina, Inc. has a 1 year low of $89.00 and a 1 year high of $148.19. The company has a market cap of $23.18 billion, a PE ratio of -17.86 and a beta of 1.15. The company’s 50-day moving average is $130.19 and its two-hundred day moving average is $120.63.

Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.24. Illumina had a negative net margin of 68.73% and a positive return on equity of 3.08%. The company had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same period in the prior year, the company posted $0.32 EPS. The company’s revenue was down 5.4% compared to the same quarter last year. Equities analysts anticipate that Illumina, Inc. will post 3.63 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ILMN. Piper Sandler lowered their price target on shares of Illumina from $200.00 to $195.00 and set an “overweight” rating on the stock in a report on Tuesday, August 13th. Barclays raised shares of Illumina from an “underweight” rating to an “equal weight” rating and set a $125.00 price target on the stock in a report on Wednesday, August 14th. JPMorgan Chase & Co. lowered their target price on shares of Illumina from $130.00 to $125.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. Citigroup upped their target price on shares of Illumina from $140.00 to $155.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $252.00 target price on shares of Illumina in a report on Thursday. One analyst has rated the stock with a sell rating, nine have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $150.05.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.